Patel Monal, Predescu Dan, Bardita Cristina, Chen Jiwang, Jeganathan Niranjan, Pritchard Melanie, DiBartolo Salvatore, Machado Roberto, Predescu Sanda
Department of Pharmacology & Internal Medicine, Division of Pulmonary and Critical Care, Rush University Medical Center, Chicago, Illinois; Department of Pharmacology, Rush University Medical Center, Chicago, Illinois.
Department of Pharmacology, Rush University Medical Center, Chicago, Illinois.
Am J Pathol. 2017 Mar;187(3):528-542. doi: 10.1016/j.ajpath.2016.11.012. Epub 2017 Jan 6.
Murine models of pulmonary arterial hypertension (PAH) that recapitulate the plexiform and obliterative arteriopathy seen in PAH patients and help in defining the molecular mechanisms involved are missing. Herein, we investigated whether intersectin-1s (ITSN) deficiency and prolonged lung expression of an ITSN fragment with endothelial cell (EC) proliferative potential (EH), present in the lungs of PAH animal models and human patients, induce formation of plexiform/obliterative lesions and defined the molecular mechanisms involved. ITSN-deficient mice (knockout/heterozygous and knockdown) were subjected to targeted lung delivery of EH via liposomes for 20 days. Immunohistochemistry and histological and morphometric analyses revealed a twofold increase in proliferative ECs and a 1.35-fold increase in proliferative α-smooth muscle actin-positive cells in the lungs of ITSN-deficient mice, transduced with the EH relative to wild-type littermates. Treated mice developed severe medial wall hypertrophy, intima proliferation, and various forms of obliterative and plexiform-like lesions in pulmonary arteries, similar to PAH patients. Hemodynamic measurements indicated modest increases in the right ventricular systolic pressure and right ventricle hypertrophy. Transcriptional and protein assays of lung tissue indicated p38-dependent activation of Elk-1 transcription factor and increased expression of c-Fos gene. This unique murine model of PAH-like plexiform/obliterative arteriopathy induced via a two-hit pathophysiological mechanism without hypoxia provides novel druggable targets to ameliorate and, perhaps, reverse the EC plexiform phenotype in severe human PAH.
目前尚缺乏能够重现肺动脉高压(PAH)患者所见丛状和闭塞性动脉病变并有助于确定相关分子机制的小鼠模型。在此,我们研究了PAH动物模型和人类患者肺中存在的相交蛋白-1s(ITSN)缺陷以及具有内皮细胞(EC)增殖潜能的ITSN片段(EH)的长期肺表达是否会诱导丛状/闭塞性病变的形成,并确定其中涉及的分子机制。通过脂质体对ITSN缺陷小鼠(基因敲除/杂合子和基因敲低)进行靶向肺内递送EH,持续20天。免疫组织化学、组织学和形态计量学分析显示,与野生型同窝小鼠相比,转导了EH的ITSN缺陷小鼠肺中增殖性EC增加了两倍,增殖性α-平滑肌肌动蛋白阳性细胞增加了1.35倍。经治疗的小鼠出现了严重的中膜壁肥厚、内膜增殖以及肺动脉中各种形式的闭塞性和丛状样病变,与PAH患者相似。血流动力学测量表明右心室收缩压适度升高,右心室肥厚。肺组织的转录和蛋白质分析表明,p38依赖的Elk-1转录因子激活以及c-Fos基因表达增加。这种通过双打击病理生理机制在无缺氧情况下诱导的独特的PAH样丛状/闭塞性动脉病变小鼠模型,为改善甚至逆转严重人类PAH中的EC丛状表型提供了新的可药物作用靶点。